<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02998775</url>
  </required_header>
  <id_info>
    <org_study_id>E7080-A001-010</org_study_id>
    <nct_id>NCT02998775</nct_id>
  </id_info>
  <brief_title>Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding</brief_title>
  <official_title>A Multicenter Phase 0 Study In Healthy Subjects and Subjects With Either Hepatic Or Renal Impairment To Obtain Plasma For Assessment In Vitro Lenvatinib Protein Binding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      E7080-A001-010 is a multicenter, parallel-group study in participants with mild, moderate, or&#xD;
      severe hepatic or renal impairment and age-, gender-, and smoking status-matched healthy&#xD;
      participants. The primary objective of the study is to obtain plasma from participants for&#xD;
      use in in vitro protein binding studies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      E7080-A001-010 is a multicenter, parallel-group study in participants with mild, moderate, or&#xD;
      severe hepatic or renal impairment and age-, gender-, and smoking status-matched healthy&#xD;
      participants. Approximately 6 participants with each degree (mild, moderate, or severe) of&#xD;
      hepatic or renal impairment will be enrolled. Two cohorts of 8 healthy participants will be&#xD;
      enrolled. One cohort of healthy participants will be matched to the hepatic-impaired&#xD;
      participants, whereas the other will be matched to the renal-impaired participants.&#xD;
&#xD;
      The study has 2 phases. The Pre-study Phase consists of a Screening Period and a Baseline&#xD;
      Period. The Study Phase consists of a 2-day Study Period. No lenvatinib will be administered&#xD;
      in this study.&#xD;
&#xD;
      The end of the study will be the date of the last study visit for the last participant in the&#xD;
      study.&#xD;
&#xD;
      The following estimates are provided:&#xD;
&#xD;
        -  From first participant in to last participant out, the study is expected to take&#xD;
           approximately one year to complete.&#xD;
&#xD;
        -  The maximum estimated duration of the study for each participant is anticipated to be&#xD;
           approximately 5 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2, 2016</start_date>
  <completion_date type="Actual">July 8, 2017</completion_date>
  <primary_completion_date type="Actual">July 8, 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with any serious adverse event and any non-serious adverse event</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Hepatic Impairment; Renal Impairment</condition>
  <arm_group>
    <arm_group_label>6 participants with mild renal impairment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Renal Impairment Mild: creatinine clearance, 50 to 80 milliliters per minute (mL/min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 participants with moderate renal impairment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Renal Impairment Moderate: creatinine clearance, 30 to 49 mL/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 participants with severe renal impairment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Renal Impairment Severe: creatinine clearance, 15 to 29 mL/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8 participants normal renal status</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Renal status normal as defined by creatinine clearance ≥ 81 mL/min, otherwise age, gender, and smoking characteristics matching renal-impaired participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 participants with mild hepatic impairment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Hepatic impairment mild: total score on the Child-Pugh classification system between 5 and 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 participants with moderate hepatic impairment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Hepatic impairment moderate: total score on the Child-Pugh classification system between 7 and 9</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 participants with severe hepatic impairment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Hepatic impairment severe: total score on the Child-Pugh classification system between 10 and 15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8 participants normal hepatic status</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Hepatic status normal, otherwise age, gender, and smoking characteristics matching hepatic-impaired participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plasma Sampling</intervention_name>
    <description>No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.</description>
    <arm_group_label>6 participants with mild hepatic impairment</arm_group_label>
    <arm_group_label>6 participants with mild renal impairment</arm_group_label>
    <arm_group_label>6 participants with moderate hepatic impairment</arm_group_label>
    <arm_group_label>6 participants with moderate renal impairment</arm_group_label>
    <arm_group_label>6 participants with severe hepatic impairment</arm_group_label>
    <arm_group_label>6 participants with severe renal impairment</arm_group_label>
    <arm_group_label>8 participants normal hepatic status</arm_group_label>
    <arm_group_label>8 participants normal renal status</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Male or Female&#xD;
&#xD;
          -  Age, at the time of Informed Consent:&#xD;
&#xD;
             i. Hepatic Impairment Participants (Including Matched Healthy Participants): 18 to 70&#xD;
             years old, inclusive ii. Renal Impairment Participants (Including Matched Healthy&#xD;
             Participants): 18 to 79 years old, inclusive&#xD;
&#xD;
          -  Non-smokers and smokers who smoke no more than 10 cigarettes per day&#xD;
&#xD;
          -  Besides diabetes and, as appropriate, renal or hepatic impairment, participants must&#xD;
             have no history of acute or chronic clinically relevant disease or condition, as&#xD;
             determined by the investigator.&#xD;
&#xD;
          -  For participants with hepatic impairment:&#xD;
&#xD;
               -  Liver cirrhosis that has been stable;&#xD;
&#xD;
               -  Platelet count &gt;30,000 cells/millimeter cubed (mm^3);&#xD;
&#xD;
               -  Total score on the Child-Pugh classification system between 5 and 6 (Group 1,&#xD;
                  mild), 7 and 9 (Group 2, moderate), and 10 and 15 (Group 3, severe)&#xD;
&#xD;
          -  For healthy participants:&#xD;
&#xD;
             • Creatinine clearance ≥ 81 milliliter per minute (mL/min)&#xD;
&#xD;
          -  For participants with renal impairment:&#xD;
&#xD;
               -  Must have a diagnosis of renal impairment that has been stable&#xD;
&#xD;
               -  Must have renal impairment in the following categories based on creatinine&#xD;
                  clearance values: mild (creatinine clearance, 50 to 80 mL/min), moderate&#xD;
                  (creatinine clearance, 30 to 49 mL/min), or severe (creatinine clearance, 15 to&#xD;
                  29 mL/min) renal impairment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Use of any new medication&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) positive&#xD;
&#xD;
          -  Presence of acute active liver disease or acute liver injury&#xD;
&#xD;
          -  History of significant cardiovascular impairment&#xD;
&#xD;
          -  Positive drug or alcohol test&#xD;
&#xD;
          -  Weight loss or gain of &gt;10% prior to Day 1&#xD;
&#xD;
          -  Receipt of blood or blood products or donation of blood or blood products&#xD;
&#xD;
        For participants with hepatic impairment:&#xD;
&#xD;
          -  History of hepatic transplant, systemic lupus erythematosus, or hepatic coma&#xD;
&#xD;
          -  Received treatment with interferon or pegylated interferon&#xD;
&#xD;
          -  Participants who have encephalopathy &gt;Grade 2, sepsis, or gastrointestinal bleeding;&#xD;
             esophageal varices &gt;Grade 2, acute hepatic failure of any etiology, history of&#xD;
             surgical portosystemic shunt, renal impairment (creatinine clearance &lt;50 mL/min&#xD;
             according to the Cockcroft-Gault formula), and rapidly deteriorating hepatic function&#xD;
&#xD;
          -  Systolic blood pressure (SBP) ≥ 160 millimeters of mercury (mmHg) and/or diastolic&#xD;
             blood pressure (DBP) ≥ 100 mmHg&#xD;
&#xD;
        For healthy participants:&#xD;
&#xD;
        • Hemoglobin level less than 12.0 grams per deciliter (g/dL)&#xD;
&#xD;
        For participants with renal impairment:&#xD;
&#xD;
          -  A history of renal transplant&#xD;
&#xD;
          -  SBP ≥ 160 mmHg and/or DBP ≥ 100 mmHg for participants with mild renal impairment; SBP&#xD;
             ≥ 180 mmHg and/or DBP ≥ 110 mmHg for participants with moderate and severe renal&#xD;
             impairment&#xD;
&#xD;
          -  Significant bleeding diathesis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Orlando Clinical Research Center, Inc.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>December 16, 2016</study_first_submitted>
  <study_first_submitted_qc>December 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2016</study_first_posted>
  <last_update_submitted>September 6, 2018</last_update_submitted>
  <last_update_submitted_qc>September 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>in vitro protein binding</keyword>
  <keyword>hepatic impairment</keyword>
  <keyword>renal impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

